Truist initiated coverage on Dianthus Therapeutics with a new price target
$DNTH
Biotechnology: Pharmaceutical Preparations
Health Care
Truist initiated coverage of Dianthus Therapeutics with a rating of Buy and set a new price target of $56.00
Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 10/14/2025 | $56.00 | Buy | Truist |
| 7/2/2025 | Outperform | William Blair | |
| 12/20/2024 | Buy | TD Cowen | |
| 10/3/2024 | $48.00 | Outperform | Oppenheimer |
| 7/26/2024 | $58.00 | Outperform | Robert W. Baird |
| 6/27/2024 | Overweight | Cantor Fitzgerald | |
| 5/16/2024 | $40.00 | Buy | H.C. Wainwright |
| 2/15/2024 | $44.00 | Buy | Stifel |
S-8 - Dianthus Therapeutics, Inc. /DE/ (0001690585) (Filer)
10-K - Dianthus Therapeutics, Inc. /DE/ (0001690585) (Filer)
8-K - Dianthus Therapeutics, Inc. /DE/ (0001690585) (Filer)
NEW YORK and WALTHAM, Mass., March 09, 2026 (GLOBE NEWSWIRE) -- Dianthus Therapeutics, Inc. (NASDAQ:DNTH) ("Dianthus" or the "Company"), a clinical-stage biotechnology company dedicated to developing next-generation therapies to transform the treatment of severe autoimmune diseases, today announced that it has commenced an underwritten public offering of $400 million of shares of its common stock or, in lieu of common stock to certain investors that so choose, pre-funded warrants to purchase shares of its common stock. In addition, Dianthus expects to grant the underwriters a 30-day option to purchase up to an additional $60 million of shares of common stock at the public offering price, l
Early GO decision reached in CAPTIVATE ahead of Q2'26 guidance based on GO criteria of 20 confirmed responders achieved with less than 40 planned participants completing open-label Part A Phase 3 registrational trial of claseprubart evaluating 300mg/2mL Q2W and 300mg/2mL Q4W in generalized Myasthenia Gravis (gMG) expected to initiate in mid-2026; top-line results anticipated in 2H'28 Phase 2 MoMeNtum trial of claseprubart in Multifocal Motor Neuropathy (MMN) ongoing; top-line results on track for 2H'26 Phase 1 healthy volunteer data for DNTH212 anticipated in 2H'26; update on indication prioritization planned for 1H'26 $514.4 million of cash as of December 31, 2025 provides runway into
Early GO decision reached ahead of Q2'26 guidance based on GO criteria of 20 confirmed responders achieved with less than 40 planned participants completing open-label Part A Key objectives achieved: Company will maintain the Part A dose of 300mg/2mL S.C. Q2W, plans to engage with regulators to remove the 600mg/4mL S.C. Q2W dose arm from Part B, and expects to enroll up to 256 patients in Part A to randomize 128 patients in Part B Independent DSMB review confirmed GO decision; no related serious infections, no clinical symptoms of autoimmune activation, and no related serious adverse events or discontinuations GO decision supports continued development of claseprubart 300mg/2mL Q2W S.C.
Truist initiated coverage of Dianthus Therapeutics with a rating of Buy and set a new price target of $56.00
William Blair initiated coverage of Dianthus Therapeutics with a rating of Outperform
TD Cowen initiated coverage of Dianthus Therapeutics with a rating of Buy
4 - Dianthus Therapeutics, Inc. /DE/ (0001690585) (Issuer)
4 - Dianthus Therapeutics, Inc. /DE/ (0001690585) (Issuer)
4 - Dianthus Therapeutics, Inc. /DE/ (0001690585) (Issuer)
SC 13D/A - Dianthus Therapeutics, Inc. /DE/ (0001690585) (Subject)
SC 13G - Dianthus Therapeutics, Inc. /DE/ (0001690585) (Subject)
SC 13G/A - Dianthus Therapeutics, Inc. /DE/ (0001690585) (Subject)
Dr. Read brings >30 years of leadership and scientific expertise in the biopharmaceutical industry Previously served as CEO and Founder of Mariana Oncology until its acquisition by Novartis in 2024 and CSO of Ra Pharma until its acquisition by UCB in 2020 NEW YORK and WALTHAM, Mass., May 22, 2025 (GLOBE NEWSWIRE) -- Dianthus Therapeutics, Inc. (NASDAQ:DNTH), a clinical-stage biotechnology company dedicated to advancing the next generation of antibody complement therapeutics to treat severe autoimmune diseases, today announced the appointment of Simon Read, Ph.D., to the Company's Board of Directors. Dr. Read is a serial entrepreneur with more than 30 years of biopharmaceutical experi
Mr. King launched the first approved biologic and C5 complement inhibitor into the Myasthenia Gravis market and helped set the foundation for the multi-billion dollar C5 franchise of Alexion Mr. King also led the commercial strategy behind the first FDA-approved, self-administered, subcutaneous biologic for gMG as the Chief Commercial Officer of Ra Pharma, acquired by UCB for $2.5 billion Mr. Kango has >26 years of industry experience spanning senior executive, commercial and business development roles in the pharmaceutical and biotechnology sector NEW YORK and WALTHAM, Mass., March 05, 2025 (GLOBE NEWSWIRE) -- Dianthus Therapeutics, Inc. (NASDAQ:DNTH), a clinical-stage biotechnology co
Dr. Stavenhagen brings over 20 years of experience in leading drug discovery initiatives, with a focus on monoclonal antibodies targeting neuro diseases Jennifer Davis Ruff also named Vice President, Head of Investor Relations & Corporate Affairs with over 20 years of experience at leading public biopharmaceutical companies NEW YORK and WALTHAM, Mass., Nov. 29, 2023 (GLOBE NEWSWIRE) -- Dianthus Therapeutics, Inc. (NASDAQ:DNTH), a clinical-stage biotechnology company dedicated to advancing the next generation of antibody complement therapeutics to treat severe autoimmune diseases, today announced the appointment of Jeffrey Stavenhagen, Ph.D., as Chief Scientific Officer. In this role, Dr.
Early GO decision reached in CAPTIVATE ahead of Q2'26 guidance based on GO criteria of 20 confirmed responders achieved with less than 40 planned participants completing open-label Part A Phase 3 registrational trial of claseprubart evaluating 300mg/2mL Q2W and 300mg/2mL Q4W in generalized Myasthenia Gravis (gMG) expected to initiate in mid-2026; top-line results anticipated in 2H'28 Phase 2 MoMeNtum trial of claseprubart in Multifocal Motor Neuropathy (MMN) ongoing; top-line results on track for 2H'26 Phase 1 healthy volunteer data for DNTH212 anticipated in 2H'26; update on indication prioritization planned for 1H'26 $514.4 million of cash as of December 31, 2025 provides runway into
Early GO decision reached ahead of Q2'26 guidance based on GO criteria of 20 confirmed responders achieved with less than 40 planned participants completing open-label Part A Key objectives achieved: Company will maintain the Part A dose of 300mg/2mL S.C. Q2W, plans to engage with regulators to remove the 600mg/4mL S.C. Q2W dose arm from Part B, and expects to enroll up to 256 patients in Part A to randomize 128 patients in Part B Independent DSMB review confirmed GO decision; no related serious infections, no clinical symptoms of autoimmune activation, and no related serious adverse events or discontinuations GO decision supports continued development of claseprubart 300mg/2mL Q2W S.C.
NEW YORK and WALTHAM, Mass., March 08, 2026 (GLOBE NEWSWIRE) -- Dianthus Therapeutics, Inc. (NASDAQ:DNTH), a clinical-stage biotechnology company dedicated to developing next-generation therapies to transform the treatment of severe autoimmune diseases, today announced a conference call and webcast to discuss the interim responder analysis results from Part A of the Phase 3 CAPTIVATE trial of claseprubart in Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) scheduled for tomorrow, Monday, March 9, 2026 at 8:00 a.m. ET. Investor Conference Call & Webcast InformationTo access the live conference call by phone, please register here. Conference call participants in the question and ans